Anxiety disorders, ranging from social phobia to post-traumatic stress disorder, are the most common psychiatric diseases in the United States. Research in mice suggests a link between the gene that encodes Glyoxylase 1 (GLO1) and increased anxiety; however, the mechanism underlying this association has remained unclear. The normal role of GLO1 is to degrade cytotoxic byproducts of glycolysis, a function which has no obvious connection to anxiety. Margaret Distler and colleagues at the University of Chicago asked whether the primary substrate of GLO1, methylglyoxal, might have undocumented neurological effects. Using a mouse model, they demonstrated that methylglyoxal stimulates robust activity from GABAA receptors, which are neuron receptors that respond to neurotransmitters. As pharmaceuticals targeting GABAA receptors are mainstays of anxiety treatment, this study provides a definitive functional link between GLO1 activity and anxiety. The team also showed that the inhibition of GLO1 in mice reduced anxious behavior, suggesting GLO1 as a potential novel therapeutic target in humans. These findings have important clinical implications not only for anxiety disorders, but also for other central nervous system diseases having proposed associations with the gene encoding GLO1, including autism, affective disorders, and schizophrenia.
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delays

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor